RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to knock out tough blood cancers
Disease control Recruiting nowThis study is testing a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) to see how well they work against aggressive forms of blood cancer, including acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), and chronic my…
Matched conditions: RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Could removing metals from the body help fight leukemia?
Disease control Recruiting nowThis early-stage study is testing whether adding metal-detoxifying drugs to standard chemotherapy can help control acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to see if lowering metal levels in the blood and bone marrow improves treatment res…
Matched conditions: RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for leukemia patients out of options
Disease control Recruiting nowThis study is testing a drug called ponatinib for adults with a type of blood cancer called chronic myeloid leukemia (CML). It's for patients whose cancer has not responded to or who could not tolerate other standard medications. The goal is to see if ponatinib can control the ca…
Matched conditions: RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC